Moneycontrol
    Moneycontrol PRO
    Loans
    Loans

    At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More

    Jump to

    • Lupin records 24% growth, revenue and profit

      Lupin has recorded 24% growth in revenues as well as profit over the second quarter of the current financial year. Kamal K Sharma, managing director of Lupin joins CNBC-TV18 to highlight the key performance points and talk of the way forward for the company.

    • Lupin Q2 PAT seen up 4% to Rs 223.3 cr

      Pharmaceutical firm Lupin is likely to report a profit after tax of Rs 223.3 crore in the second quarter of FY12, a growth of 4% as compared to Rs 215 crore in the corresponding quarter of last fiscal.

    • Lupin Sept qtr PAT seen up 9% at Rs 235 cr: Dolat Capital

      Dolat Capital has come out with its earning estimates on Pharma sector for the quarter ended September 2011. According to the research firm, Lupin September quarter net sales are expected to go up by 18.2% at Rs 1694.3 crore, year-on-year, (YoY) basis.

    • Margin pressure temporary; sales to grow 20-25%: Lupin

      Kamal Sharma, managing director, Lupin in an interview with CNBC-TV18 said, growth in this quarter was driven by markets in India, Japan and South Africa.

    • Lupin Q1 PAT seen up 7% to Rs 209 cr (YoY)

      Lupin is to announce its first quarter results. According to CNBC-TV18's estimates, the company's Q1FY12 revenues are seen up 16% to Rs 1553 crore versus Rs 1334 crore, year-on-year, YoY.

    • Mid-sized pharma margins to crimp despite sales

      Mid-sized Indian drugmakers are expected to post steady to strong revenue growth in April-June, riding healthy domestic and overseas demand, but higher would crimp margins.

    • Lupin Jun qtr PAT seen up 7% at Rs 210 cr: PINC

      PINC Research has come out with its earning estimates on pharma sector for the quarter ended June 2011. According to the research firm, Lupin June quarter net revenues are expected to go up by 13.7% at Rs 1491.7 crore, year-on-year, (YoY) basis.

    • Expect to improve EBITDA margin by 75 bps ahead: Lupin

      Lupin has declared its fourth quarter results. Kamal K Sharma, MD, Lupin says, the company’s endeavour would be to grow around 25% year-on-year (YoY) on organic basis, unless it makes some inorganic moves that could be additive. “Our attempt has always been to improve on EBITDA margins by atleast 75 bps,” he adds.

    • Lupin Q4 revenues seen up 11% to Rs 1472 cr

      Lupin is to announce its fourth quarter results. According to CNBC-TV18’s estimates, the company’s Q4 FY11 revenues are seen up 11% to Rs 1472 crore versus Rs 1328 crore, year-on-year, YoY.

    • Lupin Q4 PAT seen up 4.5% to Rs 230 cr

      Lupin is to announce its fourth quarter results. According to CNBC-TV18’s estimates, the company’s Q4 FY11 revenues are seen up 11% to Rs 1472 crore versus Rs 1328 crore, year-on-year, YoY.

    • Lupin Mar qtr PAT seen up at Rs 237.8 cr: MOST

      Motilal Oswal has come out with its earning estimates on Pharmaceuticals sector for the quarter ended March 2011. According to the research firm, Lupin March quarter sales are expected to go up by 11.4% at Rs 1431.2 crore, year-on-year, (YoY) basis.

    • Lupin Q3 PAT seen up 35% to Rs 216 cr

      Lupin has announced its third quarter results. The company's Q3FY11 revenues are seen up 15.4% to Rs 1466 crore versus Rs 1270 crore, YoY.

    • Lupin Dec qtr PAT seen up 36.6% at Rs 219cr: Angel

      Angel Broking has come out with its earning estimates on the pharmaceutical sector for the quarter ended December 2010. According to the research firm, Lupin December quarter net sales are expected to go up by 15.9% to Rs 1,454 crore, Year-on-Year, (Y-o-Y) basis.

    • Lupin Dec qtr PAT seen up 29.8% at Rs 208.5cr: Emkay

      Emkay Global Financial Services has come out with its earning estimates on pharma sector for the quarter ended December 2010. According to the research firm, Lupin December quarter sales are expected to go up by 19.3% to Rs 1515.9 crore, Year-on-Year, (Y-o-Y) basis.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347